Related Experiment Video
Updated: Apr 23, 2026
A Unified Methodological Framework for Vestibular Schwannoma Research
Published on: June 20, 2017
Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular
Sameer Agnihotri1, Isabel Gugel, Marc Remke
1Arthur & Sonia Labatt Brain Tumour Research Centre and.
Object:
Vestibular schwannomas (VS) are common benign tumors of the vestibular nerve that cause significant morbidity. The current treatment strategies for VS include surgery or radiation, with each treatment option having associated complications and side effects. The transcriptional landscape of schwannoma remains largely unknown.
Methods:
In this study the authors performed gene-expression profiling of 49 schwannomas and 7 normal control vestibular nerves to identify tumor-specific gene-expression patterns. They also interrogated whether schwannomas comprise several molecular subtypes using several transcription-based clustering strategies. The authors also performed in vitro experiments testing therapeutic inhibitors of over-activated pathways in a schwannoma cell line, namely the PI3K/AKT/mTOR pathway.
Results:
The authors identified over 4000 differentially expressed genes between controls and schwannomas with network analysis, uncovering proliferation and anti-apoptotic pathways previously not implicated in VS. Furthermore, using several distinct clustering technologies, they could not reproducibly identify distinct VS subtypes or significant differences between sporadic and germline NF2-associated schwannomas, suggesting that they are highly similar entities. The authors identified overexpression of PI3K/AKT/mTOR signaling networks in their gene-expression study and evaluated this pathway for therapeutic targeting. Testing the compounds BEZ235 and PKI-587, both novel dual inhibitors of PI3K and mTOR, attenuated tumor growth in a preclinical cell line model of schwannoma (HEI-293). In vitro findings demonstrated that pharmacological inhibition of the PI3K/AKT/mTOR pathway with next-generation compounds led to decreased cell viability and increased cell death.
Conclusions:
These findings implicate aberrant activation of the PI3K/AKT/mTOR pathway as a molecular mechanism of pathogenesis in VS and suggest inhibition of this pathway as a potential treatment strategy.
Insights
This study reveals aberrant PI3K/AKT/mTOR pathway activation in vestibular schwannomas (VS). Inhibiting this pathway shows promise as a novel therapeutic strategy for VS treatment.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Vestibular schwannomas (VS) are benign tumors of the vestibular nerve causing significant morbidity.
- Current treatments like surgery and radiation have associated complications.
- The transcriptional landscape of VS remains largely unexplored.
Purpose of the Study:
- To identify tumor-specific gene-expression patterns in VS.
- To investigate potential molecular subtypes of VS.
- To explore therapeutic targeting of identified pathways in VS.
Main Methods:
- Gene-expression profiling of 49 schwannomas and 7 normal vestibular nerves.
- Transcription-based clustering to identify molecular subtypes.
- In vitro experiments using PI3K/AKT/mTOR pathway inhibitors (BEZ235, PKI-587) in a schwannoma cell line.
Main Results:
- Over 4000 differentially expressed genes identified, highlighting proliferation and anti-apoptotic pathways.
- No reproducible VS subtypes were identified; sporadic and NF2-associated VS are molecularly similar.
- Overexpression of the PI3K/AKT/mTOR pathway was confirmed, and its inhibition reduced tumor cell viability and growth.
Conclusions:
- Aberrant PI3K/AKT/mTOR pathway activation is implicated in VS pathogenesis.
- Targeting the PI3K/AKT/mTOR pathway represents a potential therapeutic strategy for VS.
